Abstract
e60 Volume 37 Number 8S determined by using liquid chromatography-tandem mass spectrometry system. Results: There were significant differences in Cmax and AUC0-24 among four different groups (both, P < 0.001) and Cmax and AUC0-24 of tolterodine in CYP2D6*10/*10 and CYP2D6*5/*10 group were significantly higher than those in CYP2D6*wt/*wt group. Apparent oral clearance (CL/F) of tolterodine was 94.4% lower in CYP2D6*5/*10 group than that in CYP2D6*wt/*wt group. In respect to its active metabolite, Cmax and AUC0-24 had significant changes among 4 different groups (P = 0.026 and P = 0.039, respectively). Conclusions: CYP2D6 genetic polymorphism has significant effects on the pharmacokinetics of tolterodine and its active metabolite. It is recommended that physicians optimize dose of tolterodine according to CYP2D6 genotype and keep monitoring the adverse effects of tolterodine, especially in CYP2D6 poor metabolizers.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
